You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A2a Adenosine Agonist Cardiac Reperfusion Injury

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Founded in 1999, Adenosine Therapeutics LLC (ATL) is a drug discovery and development company that has developed a family of potent and selective adenosine A2A receptor agonists. With the help of STTR funding, ATL has developed a lead adenosine A2A receptor agonist, ATL-146e, that is currently in late Phase II of clinical development for use as a coronary vaso ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  2. A2a Adenosine Agonists for Diabetic Nephropathy

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetic nephropathy (DN) accounts for approximately 40% of the cases of renal failure requiring dialysis or transplantation. Moreover, diabetic nephropathy is associated with markedly higher morbidity and mortality rates. It is important to develop novel interventions to prevent complications of diabetes. Inflammation in the genesis of diabetes, as well as its ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  3. A2a Adenosine Blockers for Parkinson's Disease

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Selective antagonists of A2A adenosine receptors have proven to be effective for the treatment of Parkinson's disease (PD) both in animal models and in a human trial. However, the initial clinical trial was stopped in phase 3 due to detection of animal toxicity of KW6002. Other investigational compounds lack sufficient potency, selectivity or bioavailability to ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  4. AAV-based toolkit for targeting specific cell types

    SBC: NEUROTARGETING SYSTEMS            Topic: NINDS

    DESCRIPTION (provided by applicant): Our goal is to develop an efficient and inexpensive toolkit for ablating or reversibly inactivating specific cell types in the brain or other organs of mammals. We propose new techniques in which the genes for nitroreductase (NTR) or Drosophila allatostatin receptor (AlstR) are delivered into cells using an adeno-associated viral vector (AAV). Both are fusion ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. A Better High-level Disinfectant for Endoscopes and Other Medical Equipments/Devi

    SBC: INNOVATIVE RESEARCH SOLUTIONS INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): We are developing a novel two-part cold high-level disinfecting (HLD)/sterilization technology that will be ready to work by mixing in water, just minutes before use. Both components separately are relatively inactive,non-toxic and stable chemicals that have good shelf life, and easy handling restrictions compared to the currently used HLD products, ensuring th ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Ab-Initio Geometry Optimization of Large Molecules

    SBC: Q-CHEM INC            Topic: N/A

    DESCRIPTION (provided by applicant): Density-Functional Theory (DFT) is highly desirable for modeling biomolecules due to its accuracy. While DFT calculations of the energy are now common for large molecules, the use of DFT geometry optimizers is still confined to relatively small molecules containing no more than thirty atoms. The key limitation is that the number of steps required to reach the o ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  7. A Biological Assessment System for Cognitive Persistence

    SBC: BIOASSESSMENTS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The low frequency cardiac rhythm (LFCR) is a promising biological marker for psychological research. The primary goal of this project is to make the LFCR methodology more accessible to researchers by providing a both a product and extensive support services. In Phase I, a prototype system was built and used to collect simultaneous physiological and cognitive da ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  8. A BioPhysical Approach to Resuscitation Fluids

    SBC: BIOPHYZICA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Circulatory, hypoxemic or traumatic arrest claims an estimated 350,000 lives per year in the United States accounting for almost 15% of all deaths. Circulatory, hypoxemic, or traumatic arrests result in whole-body ischemia, most significantly global cerebral ischemia. Brain cells die when they no longer receive oxygen and nutrients from the blood. Because cereb ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Ablation Fiber Optic Probe for Surgical Maze Procedure

    SBC: INTELLIGENT OPTICAL SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is a heart rhythm abnormality that involves irregular, and often rapid heartbeats. Billions of dollars are spent annually to diagnosis and treat this disorder. Recent studies demonstrate the feasibility of treating AF and other structural heart diseases with limited, left-atrial ablation lesion sets, using alternative energy sources ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  10. ABLE Kids II- Advanced Biofidelic Lower Extremity Kids Prosthesis II

    SBC: ORTHOCARE INNOVATIONS LLC            Topic: NICHD

    DESCRIPTION (provided by applicant): The Advanced Biofidelic Lower Extremity Kids prosthesis (ABLE Kids) project will advance the state-of-the-art of pediatric prosthesis systems by advancing the demonstrably successful Phase I device and refining it intoan ultracompact and lightweight form factor suitable for pediatric use. Through the support of the Shriner's Hospitals in Salt Lake City, U ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government